SCHEMBL5344714

SCHEMBL5344714

COc1ccc(CNC(=S)[C@@H](CCC2CCCCC2)NC(=O)OC(C)(C)C)cc1OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.49
PKM P14618 1/20 0.49
RAB9A P51151 1/20 0.49
CTSD P07339 1/20 0.44
CACNA1B Q00975 3/20 0.44
PSMB1 P20618 2/20 0.42
PSMB8 P28062 2/20 0.42
PSMB9 P28065 2/20 0.42
PSMB5 P28074 2/20 0.42
REN P00797 2/20 0.41
PDE4B Q07343 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CTSK P43235 1/20 0.41
C5AR1 P21730 1/20 0.41
PSMB10 P40306 1/20 0.41
PSMB2 P49721 1/20 0.41
BCHE P06276 1/20 0.41
PPARA Q07869 1/20 0.41
PPARG P37231 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5117020 0.90 CACNA1B (0.42) CTSDCACNA1BRENALDH1A1CTSK
SCHEMBL5349089 0.87 PSMB1 (0.51) CACNA1BPSMB1PSMB8PSMB9PSMB5
SCHEMBL5348092 0.85 NPC1 (0.45) NPC1PKMRAB9ACTSDCACNA1B
SCHEMBL5344711 0.84 NPC1 (0.47) NPC1PKMRAB9ACTSDCACNA1B
SCHEMBL5351459 0.83 NPC1 (0.47) NPC1PKMRAB9ACTSDALDH1A1
Hydrochloric Acid SCHEMBL5351733 0.82 NPC1 (0.46) NPC1PKMRAB9ACTSDALDH1A1
SCHEMBL5124536 0.81 CTSK (0.47) CACNA1BRENALDH1A1CTSK
SCHEMBL4846824 0.81 CTSK (0.46) CACNA1BPSMB1PSMB8PSMB9PSMB5
SCHEMBL5124003 0.79 CTSK (0.45) CACNA1BRENCTSK
SCHEMBL5123388 0.78 CTSK (0.47) NPC1RAB9ARENCTSKBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0997147-B1 AMINO ACID DERIVATIVES ONO PHARMACEUTICAL CO (JP) 2006-03-15 EP claimed
US-20030013725-A1 Amino acid derivatives ONO PHARMACEUTICAL CO., LTD. 2003-01-16 US claimed
EP-0997147-A1 AMINO ACID DERIVATIVES Ono Pharmaceutical Co., Ltd. (JP) 2000-05-03 EP claimed
US-7166590-B2 Amino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2007-01-23 US disclosed
EP-0997147-B1 AMINO ACID DERIVATIVES ONO PHARMACEUTICAL CO (JP) 2006-03-15 EP disclosed
US-20030013725-A1 Amino acid derivatives ONO PHARMACEUTICAL CO., LTD. 2003-01-16 US disclosed
EP-0997147-A1 AMINO ACID DERIVATIVES Ono Pharmaceutical Co., Ltd. (JP) 2000-05-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013725-A1 Amino acid derivatives CACNA1B, SCN1A, SCN2A NPC1 534/4885PKM 3859/4885RAB9A 2425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.